Exagen inc. announces select preliminary full-year 2023 results and reaffirms guidance

Carlsbad, calif., jan. 07, 2024 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended december 31, 2023, and reaffirms its full-year 2023 financial guidance.
XGN Ratings Summary
XGN Quant Ranking